Neucore Bio, Inc., is an early-stage biotechnology company advancing nonviral, engineered exosomes to power the next generation of genetic medicine and aesthetic dermatology solutions. The company’s proprietary platform harnesses the innate programmability of fibroblasts and the natural intercellular signaling of exosomes to deliver nucleic acid therapeutics for disease modification and skin rejuvenation – unlocking new era of performance-driven genetic medicine and functional skincare. Based in Columbus, Ohio, Neucore has licensed novel exosome technology from The Ohio State University to power its disruptive discovery pipeline.